Newsletter SignupSearch

Chief Medical Officer Dr. Allyson Gage Interviewed by Applied Clinical Trials

In a recent interview with Applied Clinical Trials, our Chief Medical Officer Dr. Allyson Gage discussed the benefits of adaptive platform trial design, especially for diseases where the underlying biology and mechanism of disease is undetermined.

In a recent interview with Applied Clinical Trials, our Chief Medical Officer Dr. Allyson Gage discussed the benefits of adaptive platform trial design, especially for diseases where the underlying biology and mechanism of disease is undetermined.

Read the article “What You Need to Know About Adaptive Platform Design” to learn more.

Share this article:

More from CVB

American Brain Coalition Selects Cohen Veterans Bioscience Executive as New Board Member

New Artificial-Intelligence-based Tools for Monitoring Parkinson’s Disease using Wearable Devices

Peter Hoehn, Accomplished Pharmaceutical Executive, Joins Cohen Veterans Bioscience (CVB) in Newly Created Executive Leadership Role

About Cohen Veterans Bioscience (CVB)

Cohen Veterans Bioscience is a non-profit 501(c)(3) biomedical research and technology organization dedicated to advancing brain health by fast-tracking precision diagnostics and tailored therapeutics.